Zanamivir
139110-80-8
APPROVED 26-7-96……. GSK NDA 021036
A guanido-neuraminic acid that is used to inhibit neuraminidase.
Zanamivir INN /zəˈnæmɨvɪər/ is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus andinfluenza B virus. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.
The drug is approved for use for the prevention and treatment of influenza in those over the age of 7 in the United States, Canada, European Union, and many other countries. It is not recommended for people with respiratory problems and ailments.
| United States | 6294572 | APPROVED 1994-12-15 | EXPIRY 2014-12-15 |
| United States | 5360817 | 1993-07-26 | 2013-07-26 |
| Canada | 2291994 | … |
View original post 6,638 more words
DRUG REGULATORY AFFAIRS INTERNATIONAL 